Accesswire
17 Nov 2025, 13:00 UTC · 44w ago
Verdict
Headline takes no side. We score JAGX +0.40 across four claims — moderately bullish.
+0.40moderately bullish
More positive than 65% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Crofelemer demonstrated a parenteral support reduction of up to 37% in an MVID proof-of-concept trial, potentially extending the lives of infants with no existing approved treatments.
So whatPositive clinical data in an orphan disease with no competition represents a significant potential new revenue stream and catalyst for the company's valuation.
More positive than 99% of claims this week
Jaguar Health met with the FDA on October 2, 2025, to discuss an expedited approval pathway for its placebo-controlled MVID trial.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 93% of claims this week
Q3 2025 net revenue rose approximately 4% sequentially to $3.1 million, remaining flat compared to Q3 2024.
More positive than 43% of claims this week
Net loss attributable to common shareholders decreased slightly to $9.5 million from $9.9 million in the prior year period.
So whatThe decrease is marginal and the company remains heavily loss-making, representing a neutral impact on overall financial health.
Near neutral — 99% of claims this week are stronger
Which stocks this story touches
More positive than 65% of ticker scores this week
The company reported a slight increase in revenue, a decrease in net loss, and promising trial results for crofelemer in treating MVID.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
3h ago
−99.2%
Price is moving against the score
$7.06 vs $934.50 close before publication (Nov 14) · not market-adjusted
JAGX chart →
